Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COYANASDAQ:IMUXNASDAQ:MTCRNASDAQ:OPTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOYACoya Therapeutics$5.90+3.3%$5.97$4.65▼$10.24$98.68M0.4972,619 shs12,660 shsIMUXImmunic$0.92-0.3%$1.04$0.83▼$2.11$87.92M1.73719,429 shs445,534 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsOPTNOptiNose$9.60$9.13$4.82▼$20.03$97.22M-0.8862,979 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOYACoya Therapeutics+3.33%-0.51%-10.06%-7.96%-27.25%IMUXImmunic-0.34%-4.52%-16.58%-27.06%-27.75%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%OPTNOptiNose0.00%-0.93%+4.58%+66.38%-44.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOYACoya Therapeutics2.0925 of 5 stars3.55.00.00.02.00.00.0IMUXImmunic2.3654 of 5 stars3.63.00.00.02.50.80.6MTCRMetacrineN/AN/AN/AN/AN/AN/AN/AN/AOPTNOptiNose3.1712 of 5 stars1.05.00.04.22.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOYACoya Therapeutics 3.00Buy$17.00188.14% UpsideIMUXImmunic 3.25Buy$13.001,316.74% UpsideMTCRMetacrine 0.00N/AN/AN/AOPTNOptiNose 2.00Hold$9.00-6.25% DownsideCurrent Analyst Ratings BreakdownLatest MTCR, COYA, OPTN, and IMUX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOYACoya Therapeutics$3.69M26.78N/AN/A$2.47 per share2.39IMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AMTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/AOPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOYACoya Therapeutics-$7.99M-$1.07N/AN/AN/AN/A-31.63%-27.76%8/11/2025 (Estimated)IMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%N/AMTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/AOPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)Latest MTCR, COYA, OPTN, and IMUX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 million3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOYACoya TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOYACoya TherapeuticsN/A15.3115.31IMUXImmunicN/A2.712.71MTCRMetacrine0.3412.1512.15OPTNOptiNoseN/A0.790.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOYACoya Therapeutics39.75%IMUXImmunic51.82%MTCRMetacrine37.72%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipCOYACoya Therapeutics9.80%IMUXImmunic3.00%MTCRMetacrine13.80%OPTNOptiNose2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableIMUXImmunic7095.82 million87.38 millionOptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableMTCR, COYA, OPTN, and IMUX HeadlinesRecent News About These CompaniesHC Wainwright Estimates OptiNose's Q2 Earnings (NASDAQ:OPTN)May 23 at 7:49 AM | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by D. E. Shaw & Co. Inc.May 23 at 3:43 AM | marketbeat.comQ2 Earnings Estimate for OptiNose Issued By HC WainwrightMay 22 at 1:21 AM | americanbankingnews.comParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21 at 3:32 PM | finance.yahoo.comHC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)May 21 at 8:15 AM | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) is Stonepine Capital Management LLC's 8th Largest PositionMay 20, 2025 | marketbeat.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.comBridgeway Capital Management LLC Sells 227,387 Shares of OptiNose, Inc. (NASDAQ:OPTN)May 16, 2025 | marketbeat.comOptiNose (OPTN) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Renaissance Technologies LLCMay 10, 2025 | marketbeat.comOptiNose (OPTN) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comBleichroeder LP Trims Position in OptiNose, Inc. (NASDAQ:OPTN)May 7, 2025 | marketbeat.comGeode Capital Management LLC Has $576,000 Stake in OptiNose, Inc. (NASDAQ:OPTN)May 5, 2025 | marketbeat.comAcorn Capital Advisors LLC Makes New $2.82 Million Investment in OptiNose, Inc. (NASDAQ:OPTN)May 4, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by MVM Partners LLCMay 3, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comGMT Capital Corp Decreases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)April 25, 2025 | marketbeat.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTCR, COYA, OPTN, and IMUX Company DescriptionsCoya Therapeutics NASDAQ:COYA$5.90 +0.19 (+3.33%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.98 +0.08 (+1.36%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Immunic NASDAQ:IMUX$0.92 0.00 (-0.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.24%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.OptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
